Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01033318 | A Study of the Pharmacokinetics and Pharmacodynamics of MK1809 (1809-001)(COMPLETED) | PHASE1 | COMPLETED | 30 | — | — | Sep 11, 2007 | Jun 19, 2008 | Sep 26, 2018 | - | — |
| Arm | Type | Description |
|---|---|---|
| Part 1 A-1 | EXPERIMENTAL | Part 1; Panel A; Sequence 1: 2 mg MK1809 / placebo / 50 mg MK1809 / 150 mg MK1809 / 100 mg Losartan |
| Part 1 A-2 | EXPERIMENTAL | Part 1; Panel A; Sequence 2: Losartan / 10 mg MK1809 / placebo / 150 mg MK1809 / 280 mg MK1809 |
| Part 1 A-3 | EXPERIMENTAL | Part 1; Panel A; Sequence 3 2 mg MK1809 / 10 mg MK1809 / Losartan / Placebo / 280 mg MK1809 |
| Part 1 A-4 | EXPERIMENTAL | Part 1; Panel A; Sequence 4 2 mg MK1809 / Losartan / 50 mg MK1809 / 150 mg MK1809 / Placebo |
| Part 1 A-5 | EXPERIMENTAL | Part 1; Panel A; Sequence 5: Placebo / 10 mg MK1809 / 50 mg MK1809 / Losartan / 280 mg MK1809 |
| Part 1 B-1 | EXPERIMENTAL | Part 1; Panel B; Sequence 1: 5 mg MK1809 / Placebo / 100 mg MK1809 / 210 mg MK1809 / Placebo with food |
| Part 1 B-2 | EXPERIMENTAL | Part 1; Panel B; Sequence 2: 5 mg MK1809 / 25 mg MK1809/ Placebo / Losartan / 25 mg MK1809 with food |
| Part 1 B-3 | EXPERIMENTAL | Part 1; Panel B; Sequence 3: 5 mg MK1809 / Losartan / 100 mg MK1809 / 210 mg MK1809 / Losartan with food |
| Part 1 B-4 | EXPERIMENTAL | Part 1; Panel B; Sequence 4: Losartan / 25 mg MK1809/ 100 mg MK1809 / Placebo / 25 mg MK1809 with food |
| Part 1 B-5 | EXPERIMENTAL | Part 1; Panel B; Sequence 5: Placebo / 25 mg MK1809/ Losartan / 210 mg MK1809 / 25 mg MK1809 with food |
| Part 2 C-1 | EXPERIMENTAL | Part 2; Panel C; Sequence 1: 50 mg MK1809 / Placebo / 150 mg MK1809 / 210 mg MK1809 / Losartan |
| Part 2 C-2 | EXPERIMENTAL | Part 2; Panel C; Sequence 2: 50 mg MK1809 / 100 mg MK1809/ Placebo / Losartan / 280 mg MK1809 |
| Part 2 C-3 | EXPERIMENTAL | Part 2; Panel C; Sequence 3: Losartan / 100 mg MK1809/ 150 mg MK1809 / 210 mg MK1809 / Placebo |
| Part 2 C-4 | EXPERIMENTAL | Part 2; Panel C; Sequence 4: 50 mg MK1809 / Losartan / 150 mg MK1809 / Placebo / 280 mg MK1809 |
| Part 2 C-5 | EXPERIMENTAL | Part 2; Panel C; Sequence 5: Placebo / 100 mg MK1809/ Losartan / 210 mg MK1809 / 280 mg MK1809 |
| Name | Type | Description |
|---|---|---|
| MK1809 | DRUG | single oral doses of MK1809 |
| Comparator: Losartan | DRUG | single oral doses of 100 mg Losartan |
| Comparator: Placebo | DRUG | Placebo to MK1809 |
Inclusion Criteria: Part 1: * Nonsmoker for at least 6 months * Body Mass Index (BMI) less than or equal to 29 kg/m2 * In overall good health Part 2: * Body Mass Index (BMI) greater than 18kg/m2 and less than or equal to 35kg/m2 * In overall good health (patients with hypertension and/or hyperli...